CME stands for commercial medical education: and ACCME still won’t address the issue. J Med Ethics. 2016;42(3):172–3. https://pubmed.ncbi.nlm.nih.gov/26676848/

4288

Handelsman DJ. Irrational exuberance in testosterone prescribing: when will the bubble burst? Med Care. 2015;53(9):743–5. https://pubmed.ncbi.nlm.nih.gov/26270825/

4289

Shores MM, Matsumoto AM. Testosterone, aging and survival: biomarker or deficiency. Curr Opin Endocrinol Diabetes Obes. 2014;21(3):209–16. https://pubmed.ncbi.nlm.nih.gov/24722173/

4290

Perls T, Handelsman DJ. Disease mongering of age-associated declines in testosterone and growth hormone levels. J Am Geriatr Soc. 2015;63(4):809–11. https://pubmed.ncbi.nlm.nih.gov/25809947/

4291

Al-Sharefi A, Quinton R. Current national and international guidelines for the management of male hypogonadism: helping clinicians to navigate variation in diagnostic criteria and treatment recommendations. Endocrinol Metab (Seoul). 2020;35(3):526–40. https://pubmed.ncbi.nlm.nih.gov/32981295/

4292

Mok SF, Fennell C, Savkovic S, et al. Testosterone for androgen deficiency – like symptoms in men without pathologic hypogonadism: a randomized, placebo-controlled cross-over with masked choice extension clinical trial. J Gerontol A Biol Sci Med Sci. 2020;75(9):1723–31. https://pubmed.ncbi.nlm.nih.gov/31425577/

4293

Bandari J, Ayyash OM, Emery SL, Wessel CB, Davies BJ. Marketing and testosterone treatment in the USA: a systematic review. Eur Urol Focus. 2017;3(4–5):395–402. https://pubmed.ncbi.nlm.nih.gov/29174614/

4294

Huo S, Scialli AR, McGarvey S, et al. Treatment of men for “low testosterone”: a systematic review. PLoS One. 2016;11(9):e0162480. https://pubmed.ncbi.nlm.nih.gov/27655114/

4295

Bandari J, Ayyash OM, Emery SL, Wessel CB, Davies BJ. Marketing and testosterone treatment in the USA: a systematic review. Eur Urol Focus. 2017;3(4–5):395–402. https://pubmed.ncbi.nlm.nih.gov/29174614/

4296

Irwig MS, Fleseriu M, Jonklaas J, et al. Off-label use and misuse of testosterone, growth hormone, thyroid hormone, and adrenal supplements: risks and costs of a growing problem. Endocr Pract. 2020;26(3):340–53. https://pubmed.ncbi.nlm.nih.gov/32163313/

4297

Wu FCW, Tajar A, Beynon JM, et al. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med. 2010;363(2):123–35. https://pubmed.ncbi.nlm.nih.gov/20554979/

4298

Miner M, Barkin J, Rosenberg MT. Testosterone deficiency: myth, facts, and controversy. Can J Urol. 2014;21(Suppl 2):39–54. https://pubmed.ncbi.nlm.nih.gov/24978631/

4299

Salter CA, Mulhall JP. Guideline of guidelines: testosterone therapy for testosterone deficiency. BJU Int. 2019;124(5):722–9. https://pubmed.ncbi.nlm.nih.gov/31420972/

4300

Grossmann M. Serum testosterone concentrations in older men: one size does not fit all. J Clin Endocrinol Metab. 2020;105(8):dgaa400. https://pubmed.ncbi.nlm.nih.gov/32584983/

4301

Giagulli VA, Castellana M, Lisco G, Triggiani V. Critical evaluation of different available guidelines for late-onset hypogonadism. Andrology. 2020;8(6):1628–41. https://pubmed.ncbi.nlm.nih.gov/32593233/

4302

Bandari J, Ayyash OM, Emery SL, Wessel CB, Davies BJ. Marketing and testosterone treatment in the USA: a systematic review. Eur Urol Focus. 2017;3(4–5):395–402. https://pubmed.ncbi.nlm.nih.gov/29174614/

4303

Fugh-Berman A. Treating aging with testosterone. Am Fam Physician. 2017;96(7):428–30. https://pubmed.ncbi.nlm.nih.gov/29094915/

4304

The truth about testosterone replacement therapy. Fountain of youth – or harbinger of health woes? Johns Hopkins Med Lett Health After 50. 2014;29(5):1–2. https://pubmed.ncbi.nlm.nih.gov/25097952/

4305

Sansone A, Sansone M, Lenzi A, Romanelli F. Testosterone replacement therapy: the emperor’s new clothes. Rejuvenation Res. 2017;20(1):9–14. https://pubmed.ncbi.nlm.nih.gov/27124096/

4306

Layton JB, Li D, Meier CR, et al. Testosterone lab testing and initiation in the United Kingdom and the United States, 2000 to 2011. J Clin Endocrinol Metab. 2014;99(3):835–42. https://pubmed.ncbi.nlm.nih.gov/24423353/

4307

Bandari J, Ayyash OM, Emery SL, Wessel CB, Davies BJ. Marketing and testosterone treatment in the USA: a systematic review. Eur Urol Focus. 2017;3(4–5):395–402. https://pubmed.ncbi.nlm.nih.gov/29174614/

4308

Busnelli A, Somigliana E, Vercellini P. ‘Forever young’—testosterone replacement therapy: a blockbuster drug despite flabby evidence and broken promises. Human Reproduction. 2017;32(4):719–24. https://pubmed.ncbi.nlm.nih.gov/28333214/

4309

Tariq SH, Haren MT, Kim MJ, Morley JE. Andropause: is the emperor wearing any clothes? Rev Endocr Metab Disord. 2005;6(2):77–84. https://pubmed.ncbi.nlm.nih.gov/15843878/

4310

Mok SF, Fennell C, Savkovic S, et al. Testosterone for androgen deficiency – like symptoms in men without pathologic hypogonadism: a randomized, placebo-controlled cross-over with masked choice extension clinical trial. J Gerontol A Biol Sci Med Sci. 2020;75(9):1723–31. https://pubmed.ncbi.nlm.nih.gov/31425577/

4311

Fox CA, Ismail AA, Love DN, Kirkham KE, Loraine JA. Studies on the relationship between plasma testosterone levels and human sexual activity. J Endocrinol. 1972;52(1):51–8. https://pubmed.ncbi.nlm.nih.gov/5061159/

4312

Effects of sexual activity on beard growth in man. Nature. 1970;226(5248):869–70. https://pubmed.ncbi.nlm.nih.gov/5444635/

4313

Jannini EA, Screponi E, Carosa E, et al. Lack of sexual activity from erectile dysfunction is associated with a reversible reduction in serum testosterone. Int J Androl. 1999;22(6):385–92. https://pubmed.ncbi.nlm.nih.gov/10624607/

4314

Dabbs JM, Mohammed S. Male and female salivary testosterone concentrations before and after sexual activity. Physiol Behav. 1992;52(1):195–7. https://pubmed.ncbi.nlm.nih.gov/1529008/

4315

Mok SF, Fennell C, Savkovic S, et al. Testosterone for androgen deficiency – like symptoms in men without pathologic hypogonadism: a randomized, placebo-controlled cross-over with masked choice extension clinical trial. J Gerontol A Biol Sci Med Sci. 2020;75(9):1723–31. https://pubmed.ncbi.nlm.nih.gov/31425577/

4316

Handelsman DJ. Testosterone and male aging: faltering hope for rejuvenation. JAMA. 2017;317(7):699–701. https://pubmed.ncbi.nlm.nih.gov/28241336/

4317

Corona G, Guaraldi F, Rastrelli G, Sforza A, Maggi M. Testosterone deficiency and risk of cognitive disorders in aging males. World J Mens Health. 2021;39(1):9–18. https://pubmed.ncbi.nlm.nih.gov/32378366/

4318

Zhang Z, Kang D, Li H. Testosterone and cognitive impairment or dementia in middle-aged or aging males: causation and intervention, a systematic review and meta-analysis. J Geriatr Psychiatry Neurol. 2021;34(5):405–17. https://pubmed.ncbi.nlm.nih.gov/32602403/

4319

Sari Motlagh R, Quhal F, Mori K, et al. The risk of new onset dementia and/or Alzheimer disease among patients with prostate cancer treated with androgen deprivation therapy: a systematic review